《柳叶刀》子刊：我国学者通过自体/异体再生胰岛移植，治愈1型糖尿病

Core Viewpoint - The article discusses the promising results of autologous and allogeneic stem cell-derived islet therapy for Type 1 Diabetes (T1D), highlighting the need for long-term immunosuppression to prevent autoimmune attacks on transplanted islets [2][10]. Group 1: Research Background - A study published in The Lancet Diabetes & Endocrinology details the use of stem cell-derived islet therapy in three T1D patients, marking a significant advancement in diabetes treatment [3][4]. - The research utilized peripheral blood mononuclear cells (PBMC) from patients or healthy donors, reprogrammed into induced pluripotent stem cells (iPSC), to create endoderm stem cells (EnSC) for islet regeneration [4]. Group 2: Clinical Cases - Case 1 involved a 30-year-old female with a long history of T1D who initially did not respond to autologous E-islet transplantation but showed significant improvement after switching to a standard immunosuppressive regimen [6][7]. - Case 2 featured a 45-year-old male who achieved insulin independence for over 26 months following allogeneic E-islet transplantation under a standard immunosuppressive protocol, demonstrating the potential for long-term remission [8]. - Case 3 involved a 15-year-old female who, despite not fully achieving insulin independence, experienced significant improvements in blood sugar control and quality of life after receiving allogeneic E-islet transplantation [9]. Group 3: Implications and Future Directions - The study highlights the necessity of long-term immunosuppression to prevent autoimmune recurrence, even with autologous islet transplants [10]. - Future research will focus on identifying more precise immunosuppressive strategies and developing islet products that can evade immune responses without the need for ongoing immunosuppression [10].